Michael C. G. Stevens

Michael C. G. Stevens

Auto-generated profile, based on publicly available information

Michael C. G. Stevens

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
OOOdile Oberlin
Odile Oberlin
ARAnnie Rey
Annie Rey
ELElizabeth Lyden
Elizabeth Lyden
GBGianni Bisogno
Gianni Bisogno
MSMichael C.G. Stevens
Michael C.G. Stevens
JAJames R. Anderson
James R. Anderson
Purpose: To identify risk factors associated with outcome in children with metastatic rhabdomyosarcoma in a large cohort of patients Patients and Methods: Pooled data were obtained from 788 patients treated in nine studies performed by European and American cooperative groups. Clinical factors, including age, histology, site of primary, and site(s) and number of sites of metastatic disease, were correlated with event-free survival (EFS) and overall survival (OS). Results: Seven hundred eighty-eight patients were eligible for analysis. The 3-year OS and EFS were 34% (SE, 1.7) and 27% (SE, 1.6), respectively. By univariate analysis, 3-year EFS was significantly and adversely influenced by age, alveolar histology, location of primary tumor in unfavorable site (defined as extremity and “other” sites), presence of three or more sites of metastatic disease, and the presence of bone or bone marrow involvement. By multivariate analysis, EFS was strongly correlated to all factors except histology. Relative risks were 1.6 for age younger than 1 year or at least 10 years, 1.4 for unfavorable site of primary tumor, 1.4 for bone or bone marrow involvement, 1.4 for three or more metastatic sites. EFS was 50% for patients without any of these four adverse factors and was respectively 42%, 18%, 12%, and 5% in patients with one, two, three, or four factors (P < .0001). Conclusion: This analysis identified subsets of patients with metastatic rhabdomyosaroma with different outcomes to current therapy and offers a strategy to define patient candidates for experimental approaches to treatment.

14 July 2010 in JAMA
Verified
Journal Article
Closed access
PDF file
RRRaoul C. Reulen
Raoul C. Reulen
DWDavid L. Winter
David L. Winter
CFClare Frobisher
Clare Frobisher
ELEmma R. Lancashire
Emma R. Lancashire
CSCharles Stiller
Charles Stiller
MHMichael M. Hawkins
Michael M. Hawkins
Research from JAMA — Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer

20 April 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MSMichael C.G. Stevens
Michael C.G. Stevens
ARAnnie Rey
Annie Rey
NBNathalie Bouvet
Nathalie Bouvet
CECaroline Ellershaw
Caroline Ellershaw
FFFrançoise Flamant
Françoise Flamant
OOOdile Oberlin
Odile Oberlin
Purpose To improve outcome for children with nonmetastatic rhabdomyosarcoma and to reduce systematic use of local therapy. Patients and Methods Five hundred three previously untreated patients aged from birth to 18 years, recruited between 1989 and 1995, were allocated to one of six treatment schedules by site and stage. Results Five-year overall survival (OS) and event-free survival (EFS) were 71% and 57%, respectively. Primary site, T-stage, and pathologic subtype were independent factors in predicting OS by multivariate analysis. Differences between EFS and OS reflected local treatment strategy and successful re-treatment for some patients after relapse. Patients with genitourinary nonbladder prostate tumors had the most favorable outcome (5-year OS, 94%): the majority were boys with paratesticular tumors treated successfully without alkylating agents. Patients with stage III disease treated with a novel six-drug combination showed improved survival compared with the Malignant Mesenchymal Tumor 84 study (MMT 84; 5-year OS, 60% v 42%, respectively). OS was not significantly better than that achieved in the previous MMT 84 study, but 49% of survivors were cured without significant local therapy. Conclusion Selective avoidance of local therapy is justified in some patients, though further work is required to prospectively identify those for whom this is most applicable. Exclusion of alkylating agents is justified for the most favorable subset of patients. The value of the new six-drug chemotherapy combination is being evaluated further in a randomized study (MMT 95).

11 September 2007 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MHM.M. Hawkins
M.M. Hawkins
ELE.R. Lancashire
E.R. Lancashire
DWD.L. Winter
D.L. Winter
CFC. Frobisher
C. Frobisher
RRR.C. Reulen
R.C. Reulen
MJM. Jenney
M. Jenney

1 December 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MCM. Carli
M. Carli
RCRaffaella Colombatti
Raffaella Colombatti
OOO. Oberlin
O. Oberlin
GBGianni Bisogno
Gianni Bisogno
JTJ. Treuner
J. Treuner
MSM. Stevens
M. Stevens
Purpose Final results are presented from two consecutive European studies for patients with metastatic rhabdomyosarcoma (RMS) to identify prognostic variables and determine the value of high-dose chemotherapy (HDCT) in complete remission. Patients and Methods A total of 174 patients aged 3 months to 18 years participated. From 1989 to 1991, patients received four cycles of intensive multiagent chemotherapy. From 1991 to 1995, patients achieving complete remission received consolidation with HDCT. All received local therapy (surgery, radiation therapy) according to response. Results At a median follow-up of 8 years, 5-year overall survival (OS) and event-free survival (EFS) for the whole group were 24% and 20%, respectively. No statistical difference was found between HDCT and standard chemotherapy (5-year OS, 36% v 27%; EFS 29% v 23%). Univariate analysis identified primary tumor in parameningeal, extremity, or other sites; age younger than 1 year and older than 10 years; bone or bone marrow metastases; multiple metastases; and multiple sites of metastases as unfavorable prognostic factors for OS and EFS. Multivariate analysis identified unfavorable site, bone or bone marrow involvement, and unfavorable age as independently unfavorable factors. Two subgroups were identified. Those with fewer than two unfavorable factors had 5-year EFS and OS of 40% and 47%, respectively. Patients with ≥ two unfavorable factors had 5-year EFS and OS of 7.5% and 9%, respectively. Conclusion A minority of patients with metastatic RMS have better survival than overall results for this population suggest. Those in the highest risk group have such poor survival that they are candidates for first-line novel therapies. There is no evidence that consolidation with HDCT improves outcome.

1 April 1998 in European Journal of Cancer
Verified
Journal Article
Closed access
MSM.C.G Stevens
M.C.G Stevens
HMH Mahler
H Mahler
SPS Parkes
S Parkes